Maintenance with cetuximab monotherapy appeared to improve PFS and OS in patients with metastatic colorectal cancer. A systematic review reported that immune checkpoint inhibitor therapy shows promising results in metastatic CRC. Nimotuzumab plus gemcitabine demonstrated a favorable safety profile in patients with metastatic pancreatic cancer. The rate of colorectal cancer (CRC) screenings decreased by more than 20% during the COVID-19 pandemic. A study found key tumor heterogeneities, including Ki-67 indices, might contribute to disease progression in GEP-NETs. Pranob Bhattacharya discusses zolbetuximab, a first-in-class investigational therapy for the treatment of gastric cancer. The Oncology Brothers speak with Cathy Eng, MD, about treatment of metastatic colorectal cancer with fruquintinib. Results from a recent study suggest a novel therapy that may effectively treat pancreatic ductal adenocarcinoma. Daily vitamin D3 supplementation was associated with reduced risk of relapse or death in digestive tract cancer. An analysis found that esophageal cancer rates have declined in the United States since 2004. Lu-177-dotatate in PRRT appeared to treat GEP-NETs, though prior internal radiation may impede responses or worsen survival. Researchers identified a circRNA signature as a potential biomarker for GEP-NETs. A study evaluated the predictive ability of the combined SMI and PNI to assess survival in advanced gastric cancer patients. Treatment with avelumab improved progression-free survival in patients with mCRC. Patients diagnosed with colorectal liver metastases in expert hospitals receive better treatment. Preoperative induction chemotherapy followed by chemoradiotherapy prior to esophagectomy does not improve survival. A study found that adding docetaxel to S-1 as postoperative chemotherapy improves survival in gastric cancer patients. A study investigated whether BMI is related to postoperative opioid use after treatment for peritoneal carcinomatosis. Patients with advanced stage gastroenteropancreatic neuroendocrine tumors appear to benefit from PRRT. Researchers assessed whether the aggressive warming of core body temperature reduces complications in esophageal cancer.